TipRanks on MSN13h
iX Biopharma’s iXB 401: A Breakthrough in Drug DeliveryX Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...
Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback